phospho-LATS1+LATS2 (Thr1079 +Thr1041)抗体特异性结合抗原:抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞,通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而,抗体可通过与病毒或**的特异性结合,直接发挥中和病毒的作用。
产物编号xy- 7913R
英文名称phospho-LATS1+LATS2 (Thr1079 +Thr1041)
中文名称磷酸化肿瘤抑制基因尝础罢厂1/尝础罢厂2抗体
别 名LATS1 +LATS2 (phospho T1079 + T1041); Serine/threonine protein kinase LATS2; KPM; Large tumor supressor, homolog 1; LATS, large tumor suppressor, homolog 1 (Drosophila); LATS, large tumor suppressor, homolog 2 (Drosophila); LATS1 +LATS2 (phospho T1079 + T1041); p-LATS1 +LATS2(Thr1079 +Thr1041); RGD1564085; Serine/threonine protein kinase LATS1; WARTS; WARTS protein kinase; wts; 4932411G09Rik; AV277261; AW208599; AW228608; FLJ13161; LATS1_HUMAN.
JournalPMIDIFApplicationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology (2014)248750963.6490WB
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 细胞生物 信号转导 细胞周期蛋白 激酶和磷酸酶
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
phospho-LATS1+LATS2 (Thr1079 +Thr1041)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量124kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human LATS1 around the phosphorylation site of Thr1079:EF(P-T)FR
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
phospho-LATS1+LATS2 (Thr1079 +Thr1041)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein MST1/MST2, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor.
Function:
Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function.
Subunit:
Complexes with CDK1 in early mitosis. LATS1-associated CDK1 has no mitotic cyclin partner and no apparent kinase activity. Binds phosphorylated ZYX, locating this protein to the mitotic spindle and suggesting a role for actin regulatory proteins during mitosis. Binds to and colocalizes with LIMK1 at the actomyosin contractile ring during cytokinesis. Interacts (via PPxY motif 2) with YAP1 (via WW domains). Interacts with MOB1A and MOB1B. Interacts with LIMD1, WTIP and AJUBA.
Subcellular Location:
Cytoplasm, cytoskeleton, centrosome. Note=Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis.
Tissue Specificity:
Expressed in all tissues examined except for lung and kidney.
Post-translational modifications:
Autophosphorylated and phosphorylated during M-phase of the cell cycle. Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in its activation. Phosphorylated upon DNA damage, probably by ATM or ATR. Phosphorylation at Ser-464 by NUAK1 and NUAK2 leads to decreased protein level and is required to regulate cellular senescence and cellular ploidy.
Similarity:
Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 protein kinase domain.
Contains 1 UBA domain.
SWISS:
O95835
Gene ID:
9113
Database links:
UniProtKB/Swiss-Prot: O95835.1
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
phospho-LATS1+LATS2 (Thr1079 +Thr1041)抗体(antibody,
Ab)是由效应B细胞(效应**B细胞)分泌,机体用于抵御外来物质,如病毒,**等抗原,结构呈“驰”字型的球状蛋白质,仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质,均被称作抗原,因此对于抗抗体(能够结合抗体的抗体)来说,抗体本身也是一种抗原物质。
phospho-LATS1+LATS2 (Thr1079 +Thr1041)抗体普通抗体重链和轻链的结构
重链结构:普通的**球蛋白具有2条重链(H链),分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型,对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构: 普通**球蛋白具有2条轻链(L链),分子质量约25kDa,有κ链和λ链两种亚型,这两种轻链决定了Ig的亚型类别(IgG1,IgG2,IgG3,IgG4)。一个天然的Ig分子两条轻链总是相同的,但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同,正常人血清**球蛋白κ链:λ链约为2:1,而在小鼠的比例为20:1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应;经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段(fragment of antigen binding,Fab),相当于抗体分子的两个臂,由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段(fragment crystallizable,Fc)相当于Ig的CH2和CH3结构域,是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区,以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域,相当于Y字结构下面那一部分。
合格 GABRG3 G氨基丁酸受体γ3/GABAA Rγ3抗体
合格 GABRR1 G氨基丁酸A型受体rho1/GABAA Rρ1抗体
合格 KCTD8 钾离子通道多聚体结构域蛋白8抗体
合格 ADAMTS1 整合素样金属蛋白酶与凝血酶1型抗体
合格 CNGB3 环核苷酸门控阳离子通道蛋白β3/CNG-β3抗体
合格 合格 GRINA 谷氨酸受体相关蛋白1抗体
合格 NR3B 谷氨酸受体3B抗体
合格 NMDAR3A + 3B 谷氨酸受体3A+3B抗体
合格 P2RX7 嘌呤受体P2X7抗体
合格 合格 P2RX1 三磷酸腺苷受体受体P2X1抗体
合格 合格 P2X5b 三磷酸腺苷受体P2X5b抗体
合格 合格 P2RX6 三磷酸腺苷受体P2X6抗体
合格 CHRNA10 烟碱型乙酰胆碱受体α10/AChRα10抗体
合格 CHRNA9 烟碱型乙酰胆碱受体α9/AChRα9抗体
合格 合格 SLC35C2 溶质载体蛋白家族35成员C2抗体
合格 TOP1MT 线粒体DNA拓普西异构酶Ⅰ抗体
合格 UNC80 UNC80蛋白抗体
合格 SCN2B 神经元电压门控钠通道蛋白β2/Na+ CP type IIβ抗体
合格 SLC38A2 氨基酸转运蛋白2抗体
合格 合格 ACCN2 脑钠通道蛋白2抗体
合格 ACCN4 脑钠通道蛋白4抗体
合格 TRAF1 肿瘤坏死因子受体相关因子1抗体
合格 ASIC3 酸敏感离子通道蛋白3抗体
合格 合格 DLGAP2 PSD95结合蛋白2抗体
合格 合格 TRAF2 肿瘤坏死因子受体相关因子2抗体
合格 DLGAP4 PSD95结合蛋白4抗体
合格 ZNF312 锌指蛋白312抗体
合格 TXLNB β-taxilin蛋白抗体
合格 PDGFAA + PDGFBB 血小板源性生长因子AA+BB抗体
合格 ANO9 p53诱导蛋白5抗体
合格 TPH 色氨酸羟化酶抗体
合格 Calcyphosine 1 钙磷蛋白1抗体
合格 GPR18 G蛋白偶联受体18抗体
合格 KIR5.1 细胞内流钾通道蛋白Kir5.1抗体
合格 ST18 肿瘤抑制蛋白18抗体
合格 FOXD1 叉头蛋白D1抗体
合格 GRP78 葡萄糖调节蛋白78抗体(热休克蛋白70蛋白5)
合格 SALL1 锌指转录蛋白Sall1抗体
合格 ZNF342 锌指蛋白342抗体